A Phase 4 interventional study of Ferinject and Sodium Chloride 0.9% Inj in Myocardial Infarction, Acute, sponsored by Wroclaw Medical University. Recruiting at 43 sites in Poland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Wroclaw Medical University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Myocardial Infarction with a site in Poland — 17 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Poland.
Among the 89 studies in Myocardial Infarction with a site in Poland, this one is the 40th largest by planned enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 in phase 4, reaches primary completion later than 3 of the 19 other live ones, and was the 74th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →17 of the 89 studies in Myocardial Infarction with a site in Poland are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Poland, Ireland, Latvia and 2 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
Abcentra · Sites in Poland, United States, Czechia and 6 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
MEDICOVER SP Z O.O. · Sites in Poland
Ages 18–85
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 30 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 1,012 across the 77 interventional studies, 490 across the 12 observational. Of the 66 that completed or were terminated, 29 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 89 have an industry lead sponsor. The 10 most frequent:
Wroclaw Medical University is the lead sponsor of 99 studies on the registry; 29 are open to participants now.
Wroclaw Medical University has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
9 of the studies in Myocardial Infarction with a site in Poland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07203846Collegium Medicum w BydgoszczyModulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor | 2026-12-31 |
| NCT06956807ViscofanSafety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells | 2026-12-31 |
| NCT07617376Wroclaw Medical UniversityPre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 89 studies in Myocardial Infarction with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Non-commercial, multicentre, randomised, double-blind, parallel group, placebo-controlled clinical trial. Eligible patients were randomly assigned (1:1) using a secure, central, interactive, web-based response system, to intervention FCM or placebo arm. Time of observation: minimum of 8 months up to a maximum of 36 months.
Primary Study Objective: Primary:
Evaluation of the effect of i.v. FCM treatment compared with placebo on the risk of death, the risk of heart failure events (HFE*) (number of events and time to first event), NTproBNP concentration and the change in quality of life (QoL) assessed using EQ-5D during the follow-up up to 36-months in patients with recent AMI and ID (with an implementation of a win ratio approach in a hierarchical descending order).
*HFE: unplanned hospitalization for HF (including unplanned visit at emergency department due to HF), ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs/symptoms).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of ≥3 factors (confirmed within up to 4 weeks before randomisation) (note: at least one of a-c must be present):
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
an i.v. 15-minute infusion of 20 mL Ferinject (containing 1000 mg of FCM) diluted in 50 mL of NaCl 0.9%
Drug: Ferinject
70 mL of i.v. NaCl 0.9% infusion
Drug: Sodium Chloride 0.9% Inj
The first dose of either FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7). If safety criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
The first dose of placebo will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7).
Time to all-cause death assessed up to maximum 36-months follow-up;
Defined as: (with an implementation of a win ratio approach in a hierarchical descending order): 1. Time to all-cause death assessed up to maximum 36-months follow-up; 2. Number of HFE assessed up to maximum 36-months follow-up; 3. Time to first HFE assessed up to maximum 36-months follow-up; 4. Changes in serum NT-proBNP concentration from the start of the follow-up to the end of participation in the study assessed as the area under the curve; 5. Changes in quality of life (QoL) measured using the EQ-5D questionnaire from the start of the follow-up to the end of participation in the study assessed as the area under the curve. * HFE: unplanned hospitalization for HF (including unplanned visit at emergency department due to HF), ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs/symptoms).
Time frame: up to 36 months
Number of HFE assessed up to maximum 36-months follow-up
Number of HFE
Time frame: up to 36 months
Time to first HFE assessed up to maximum 36-months follow-up
Time to first HFE
Time frame: up to 36 months
Changes in serum NT-proBNP concentration from the start of the follow-up to the end of participation in the study assessed as the area under the curve
Changes in serum NT-proBNP
Time frame: up to 36 months
Changes in quality of life (QoL) measured using the EQ-5D questionnaire from the start of the follow-up to the end of participation in the study assessed as the area under the curve
Changes in quality of life
Time frame: up to 36 months
First unplanned HF hospitalisation or unplanned visit at emergency department due to HF or CV death during the follow-up (time-to-event model)
First unplanned HF hospitalisation or unplanned visit at emergency
Time frame: up to 36 months
All unplanned HF hospitalisations and unplanned visit at emergency department due to HF and CV death during the follow-up (recurrent event model);
All unplanned HF hospitalisations and unplanned visit at emergency
Time frame: up to 36 months
All unplanned HF hospitalisations and unplanned visit at emergency department due to HF during the follow-up (recurrent event model)
All unplanned HF hospitalisations and unplanned visit at emergency department
Time frame: up to 36 months
All unplanned HF hospitalisations during the follow-up (recurrent event model);
All unplanned HF hospitalisations
Time frame: up to 36 months
CV death during the follow-up
CV death
Time frame: up to 36 months
First unplanned CV hospitalisation or CV death during the follow-up (time-to-event model);
First unplanned CV hospitalisation or CV death during the follow-up
Time frame: up to 36 months
All unplanned CV hospitalisations and CV death during the follow-up (recurrent event model);
All unplanned CV hospitalisations and CV death during the follow-up
Time frame: up to 36 months
All unplanned CV hospitalisations during the follow-up (recurrent event model);
All unplanned CV hospitalisations during the follow-up (recurrent event model);
Time frame: up to 36 months
Non-CV death during the follow-up
Non-CV death during the follow-up
Time frame: up to 36 months
All-cause death during the follow-up up
All-cause death during the follow-up
Time frame: up to 36 months
Ambulatory significant intensification of diuretic therapy during the follow-up
Ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs/symptoms) during the follow-up.
Time frame: up to 36 months
Changes in serum NT-proBNP concentration assessed as the area under the curve during the follow-up;
Changes in serum NT-proBNP concentration assessed as the area under the curve during the follow-up;
Time frame: up to 36 months
Changes in quality of life (QoL) measured using the EQ-5D questionnaire assessed as the area under the curve during the follow-up;
Changes in quality of life (QoL) measured using the EQ-5D questionnaire assessed as the area under the curve during the follow-up;
Time frame: up to 36 months
Cost-effectiveness measures during the follow-up
Cost-effectiveness measures during the follow-up.
Time frame: up to 36 months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.
Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 51 months is above that.
Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose
Wroclaw Medical University